Complement-Based Drug Development Summit leaderboard
  • Tuesday, October 6, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 35

Cipla Wins US Approval for Generic Ventolin Inhaler

Apr 23, 2026
Cipla Limited and its wholly owned subsidiary Cipla USA Inc. have secured final approval from the U.S. Food and Drug Administration (USFDA) for their Abbreviated New Drug Application…
Read More...

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal as Industry Leaders Convene at TRP Summit

Apr 23, 2026
Radiopharmaceuticals continue to reshape oncology strategy. Regeneron’s entry into radiopharma through its partnership with Telix investing $40M upfront across up to four oncology…
Read More...

MSD, Google Cloud Forge $1B AI Partnership

Apr 23, 2026
MSD, known as Merck & Co., Inc. in the United States, has entered into a major multi-year partnership with Google Cloud aimed at transforming the pharmaceutical giant into a fully…
Read More...

AbbVie to Invest $1.4 Billion in North Carolina Campus

Apr 23, 2026
AbbVie has announced a major $1.4 billion investment to establish a new pharmaceutical manufacturing campus in Durham, marking a significant expansion of its U.S. production…
Read More...

BioAegis and Prenosis Partner to Advance Precision ARDS Therapy

Apr 23, 2026
Clinical-stage biotech firm BioAegis Therapeutics has entered a strategic collaboration with Prenosis to accelerate the development of a precision medicine approach for inflammatory…
Read More...

FDA Approves Merck’s New Two-Drug HIV Treatment Option

Apr 23, 2026
The U.S. Food and Drug Administration has approved IDVYNSO, a new once-daily, single-tablet regimen developed by Merck, for the treatment of adults living with HIV-1. The therapy is…
Read More...

FDA Expands Tzield Use to Younger Children with Type 1 Diabetes

Apr 23, 2026
The U.S. Food and Drug Administration has approved an expanded indication for Tzield (teplizumab-mzwv), allowing its use in children as young as one year old to delay the onset of stage…
Read More...

Boehringer Expands AI Footprint With London Innovation Hub

Apr 22, 2026
Boehringer Ingelheim has announced a major expansion of its global Computational Innovation network with the launch of a new artificial intelligence (AI) and machine learning (ML)…
Read More...

FDA Priority Review for PADCEV Combo in Bladder Cancer

Apr 22, 2026
The U.S. Food and Drug Administration has granted Priority Review to a supplemental Biologics License Application (sBLA) filed by Astellas Pharma Inc. and Pfizer Inc., seeking to expand…
Read More...

Biocon Wins Canada Approval for Two Denosumab Biosimilars

Apr 22, 2026
Biocon Limited has secured regulatory approval in Canada for two of its denosumab biosimilars, marking a significant expansion of its global biosimilars portfolio. The company announced…
Read More...
Previous 1 … 33 34 35 36 37 … 956 Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Sanofi, Regeneron Expand Antibody Collaboration With $8B Deal
  • Abogen, Novartis Sign $7.2B RNA Therapeutics Deal
  • CAS, Novartis Partner on AI-Ready Reaction Data for Drug Discovery
  • SK pharmteco Invests $200M to Expand U.S. Drug Manufacturing
  • AstraZeneca Invests $2B in Summit Therapeutics for Cancer Research

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.